BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 18549979)

  • 1. Challenges in design of biochemical assays for the identification of small molecules to target multiple conformations of protein kinases.
    Chène P
    Drug Discov Today; 2008 Jun; 13(11-12):522-9. PubMed ID: 18549979
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A new paradigm for protein kinase inhibition: blocking phosphorylation without directly targeting ATP binding.
    Bogoyevitch MA; Fairlie DP
    Drug Discov Today; 2007 Aug; 12(15-16):622-33. PubMed ID: 17706543
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Kinase-targeted libraries: the design and synthesis of novel, potent, and selective kinase inhibitors.
    Akritopoulou-Zanze I; Hajduk PJ
    Drug Discov Today; 2009 Mar; 14(5-6):291-7. PubMed ID: 19121409
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disease mechanisms and emerging therapies: protein kinases and their inhibitors in myocardial disease.
    Anderson ME; Higgins LS; Schulman H
    Nat Clin Pract Cardiovasc Med; 2006 Aug; 3(8):437-45. PubMed ID: 16874356
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural approaches to obtain kinase selectivity.
    Norman RA; Toader D; Ferguson AD
    Trends Pharmacol Sci; 2012 May; 33(5):273-8. PubMed ID: 22503441
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predicting polypharmacology by binding site similarity: from kinases to the protein universe.
    Milletti F; Vulpetti A
    J Chem Inf Model; 2010 Aug; 50(8):1418-31. PubMed ID: 20666497
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The ATP site of protein kinases as target for drug development: from natural compounds to gleevec.
    Granot Y
    Isr Med Assoc J; 2002 Aug; 4(8):633-5. PubMed ID: 12183872
    [No Abstract]   [Full Text] [Related]  

  • 8. [Progress in the design of selective ATP-competitive kinase inhibitors].
    Deng XQ; Xiang ML; Jia R; Yang SY
    Yao Xue Xue Bao; 2007 Dec; 42(12):1232-6. PubMed ID: 18338633
    [TBL] [Abstract][Full Text] [Related]  

  • 9. kinDOCK: a tool for comparative docking of protein kinase ligands.
    Martin L; Catherinot V; Labesse G
    Nucleic Acids Res; 2006 Jul; 34(Web Server issue):W325-9. PubMed ID: 16845019
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rational design of inhibitors that bind to inactive kinase conformations.
    Liu Y; Gray NS
    Nat Chem Biol; 2006 Jul; 2(7):358-64. PubMed ID: 16783341
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Kinase inhibitors].
    Hagiwara M; Usuki H
    Tanpakushitsu Kakusan Koso; 2007 Oct; 52(13 Suppl):1708-12. PubMed ID: 18051404
    [No Abstract]   [Full Text] [Related]  

  • 12. The design, annotation, and application of a kinase-targeted library.
    Xi H; Lunney EA
    Methods Mol Biol; 2011; 685():279-91. PubMed ID: 20981529
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aurora-A kinase inhibitor scaffolds and binding modes.
    Yan A; Wang L; Xu S; Xu J
    Drug Discov Today; 2011 Mar; 16(5-6):260-9. PubMed ID: 21147253
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Kinase inhibitor selectivity.
    Bhagwat SS
    Curr Opin Investig Drugs; 2009 Dec; 10(12):1266-8. PubMed ID: 19943198
    [No Abstract]   [Full Text] [Related]  

  • 15. High affinity targets of protein kinase inhibitors have similar residues at the positions energetically important for binding.
    Sheinerman FB; Giraud E; Laoui A
    J Mol Biol; 2005 Oct; 352(5):1134-56. PubMed ID: 16139843
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Functional classification of protein kinase binding sites using Cavbase.
    Kuhn D; Weskamp N; Hüllermeier E; Klebe G
    ChemMedChem; 2007 Oct; 2(10):1432-47. PubMed ID: 17694525
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tinkering outside the kinase ATP box: allosteric (type IV) and bivalent (type V) inhibitors of protein kinases.
    Cox KJ; Shomin CD; Ghosh I
    Future Med Chem; 2011 Jan; 3(1):29-43. PubMed ID: 21428824
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structural biology contributions to tyrosine kinase drug discovery.
    Cowan-Jacob SW; Möbitz H; Fabbro D
    Curr Opin Cell Biol; 2009 Apr; 21(2):280-7. PubMed ID: 19208462
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of structure in kinase-targeted inhibitor design.
    Pratt DJ; Endicott JA; Noble ME
    Curr Opin Drug Discov Devel; 2004 Jul; 7(4):428-36. PubMed ID: 15338952
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Small molecules keep mitotic kinases in check.
    Strebhardt K
    ACS Chem Biol; 2006 Dec; 1(11):683-6. PubMed ID: 17184131
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.